-
Notifications
You must be signed in to change notification settings - Fork 3
/
Copy pathwhy.qmd
68 lines (62 loc) · 4.47 KB
/
why.qmd
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
# Open source: the what and why
'Open-source' software is software covered by a license that legally allows
access and inspection of the software's source code. The many varieties of
open-source licenses determine what you can then do with the software's source
code, i.e. copy, modify, contribute or redistribute. Being able to view and
then do something with source code wasn't always so. The term 'open-source' has
been in use at least since the 1990's [@Peterson2018] and the principles behind
the term pre-date computer software. Thus, as long as there has been source
code there have been efforts to make it 'open-source'.
As computing systems became widely adopted in universities and beyond, the
value of freely accessing the IT's source code became apparent. This effort
was described as making software 'free' by Richard Stallman and formalised
by the creation of the Free Software Foundation in 1985, including the creation
of a legally enforceable licenses (the GNU Public License) to enshrine source
code as 'free', that is, having the freedom to access. Although this effort was
the genesis of today's open-source communities, many people mistakenly
understood 'free' to mean gratis, which was incorrect: most open-source
licenses allow the software to be sold for a fee [@OSI]. As is the case,
even if the main goal of open source is not creating software gratis, it
so happens that the majority of open-source software is made available at no
cost. Regardless of whether it is sold for a fee or not, the term 'open-source'
is the preferred term by most with respect to software with a license that
allows access to the source code.
Readers coming from the pharmaceutical industry probably perceive a
contradiction here: how can software which is typically gratis to use, have any
intrinsic value to either business or private users? Fair enough: this industry
depends on capital investment which then depends on retaining the details of
their drugs and production secret. The difference lies in the utility of (some)
software, versus, in this example, a drug or therapy. Certain categories of
software enable the creation of new value. Obvious examples being programming
languages enabling creation of specialized applications which can support a
specific business process, e.g. C, Python, R and many others. The ability to
use and improve these open source languages freely accelerate in multiple
dimensions the ability to create business value, e.g. specialized smart phone
apps that offers a service to end-users. Imagine if you have an idea for a smart
phone app, but before you can write a line of code, you need to buy a license
to install that language. And after investing the time and money to access this
language you realise it doesn't work as well as you need for your particular
app. Or worse yet, it has a bug which renders it unfit for your purpose.
Little chance you can resolve this quickly. Open-source software does not
have these restrictions so you can focus all your resources on end-user value,
not the tools needed for creation.
Open-sourcing software solutions is also a mindset approach. As you use
available open-source code, you are using bits and pieces to create a piece
of software/analytics that is greater than the individual parts. By
open-sourcing your solution, you give others the opportunity to build on top of
your work, as well as improve your work itself by contributing. Ultimately,
this comes back around to yourself: What you have available at your disposal
is now greater, than if you worked in a silo.
Open-source is also a step towards ensuring reproducibility. Consider an
analysis done in a propriety language by a pharmaceutical company. An academic
accessing the same data through a data sharing initiative may find results
that contradict those done using the propriety tool. Such a researcher would
not be able reproduce the results nor investigate the source of the
discrepancy---and in fact any attempt to reproduce results is dependent on
the for-profit company providing a license to generate that
insight [@Rodrigues2022].
The drugs and therapies manufactured by the pharmaceutical industry are the
equivalent of a smart phone app: they provide end-user value. It’s sound
business logic to open source the tools used to create these products: remove
the restrictions to creating drugs and enable each company to sharpen their
focus on developing and delivering them.